CN112745394A - 一种重组类人胶原蛋白及其制备方法和应用 - Google Patents
一种重组类人胶原蛋白及其制备方法和应用 Download PDFInfo
- Publication number
- CN112745394A CN112745394A CN202110128601.0A CN202110128601A CN112745394A CN 112745394 A CN112745394 A CN 112745394A CN 202110128601 A CN202110128601 A CN 202110128601A CN 112745394 A CN112745394 A CN 112745394A
- Authority
- CN
- China
- Prior art keywords
- gly
- collagen
- human
- recombinant human
- rhlec
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010035532 Collagen Proteins 0.000 title claims abstract description 58
- 102000008186 Collagen Human genes 0.000 title claims abstract description 57
- 229920001436 collagen Polymers 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 27
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 26
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 26
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 16
- 230000002441 reversible effect Effects 0.000 claims abstract description 10
- 239000000654 additive Substances 0.000 claims abstract description 8
- 230000000996 additive effect Effects 0.000 claims abstract description 7
- 239000002537 cosmetic Substances 0.000 claims abstract description 5
- 241000894006 Bacteria Species 0.000 claims description 18
- 239000006228 supernatant Substances 0.000 claims description 15
- 230000014509 gene expression Effects 0.000 claims description 13
- 150000001413 amino acids Chemical group 0.000 claims description 11
- 239000002773 nucleotide Substances 0.000 claims description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 239000013604 expression vector Substances 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 230000003796 beauty Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 15
- 238000000746 purification Methods 0.000 abstract description 13
- 102000016942 Elastin Human genes 0.000 abstract description 8
- 108010014258 Elastin Proteins 0.000 abstract description 8
- 229920002549 elastin Polymers 0.000 abstract description 8
- 230000021164 cell adhesion Effects 0.000 abstract description 6
- 230000037314 wound repair Effects 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 230000003252 repetitive effect Effects 0.000 abstract description 3
- 238000004113 cell culture Methods 0.000 abstract description 2
- 239000011159 matrix material Substances 0.000 abstract description 2
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000009707 neogenesis Effects 0.000 abstract 1
- 108010037850 glycylvaline Proteins 0.000 description 35
- VOBYAKCXGQQFLR-LSJOCFKGSA-N Ile-Gly-Val Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O VOBYAKCXGQQFLR-LSJOCFKGSA-N 0.000 description 32
- FEPSEIDIPBMIOS-QXEWZRGKSA-N Pro-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 FEPSEIDIPBMIOS-QXEWZRGKSA-N 0.000 description 32
- SJRUJQFQVLMZFW-WPRPVWTQSA-N Val-Pro-Gly Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O SJRUJQFQVLMZFW-WPRPVWTQSA-N 0.000 description 32
- HMHRTKOWRUPPNU-RCOVLWMOSA-N Gly-Ile-Gly Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O HMHRTKOWRUPPNU-RCOVLWMOSA-N 0.000 description 30
- YGHSQRJSHKYUJY-SCZZXKLOSA-N Gly-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN YGHSQRJSHKYUJY-SCZZXKLOSA-N 0.000 description 30
- 108010029020 prolylglycine Proteins 0.000 description 30
- DHDOADIPGZTAHT-YUMQZZPRSA-N Gly-Glu-Arg Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DHDOADIPGZTAHT-YUMQZZPRSA-N 0.000 description 17
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 17
- NLKVNZUFDPWPNL-YUMQZZPRSA-N Glu-Arg-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O NLKVNZUFDPWPNL-YUMQZZPRSA-N 0.000 description 16
- SWQALSGKVLYKDT-UHFFFAOYSA-N Gly-Ile-Ala Natural products NCC(=O)NC(C(C)CC)C(=O)NC(C)C(O)=O SWQALSGKVLYKDT-UHFFFAOYSA-N 0.000 description 14
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 14
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 10
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- WMYJZJRILUVVRG-WDSKDSINSA-N Ala-Gly-Gln Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O WMYJZJRILUVVRG-WDSKDSINSA-N 0.000 description 5
- AQPVUEJJARLJHB-BQBZGAKWSA-N Arg-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N AQPVUEJJARLJHB-BQBZGAKWSA-N 0.000 description 5
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 5
- NKNILFJYKKHBKE-WPRPVWTQSA-N Arg-Gly-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O NKNILFJYKKHBKE-WPRPVWTQSA-N 0.000 description 5
- AYFVRYXNDHBECD-YUMQZZPRSA-N Asp-Leu-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O AYFVRYXNDHBECD-YUMQZZPRSA-N 0.000 description 5
- PGPJSRSLQNXBDT-YUMQZZPRSA-N Gln-Arg-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O PGPJSRSLQNXBDT-YUMQZZPRSA-N 0.000 description 5
- GNMQDOGFWYWPNM-LAEOZQHASA-N Gln-Gly-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@@H](N)CCC(N)=O)C(O)=O GNMQDOGFWYWPNM-LAEOZQHASA-N 0.000 description 5
- LJPIRKICOISLKN-WHFBIAKZSA-N Gly-Ala-Ser Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O LJPIRKICOISLKN-WHFBIAKZSA-N 0.000 description 5
- FZQLXNIMCPJVJE-YUMQZZPRSA-N Gly-Asp-Leu Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O FZQLXNIMCPJVJE-YUMQZZPRSA-N 0.000 description 5
- DTRUBYPMMVPQPD-YUMQZZPRSA-N Gly-Gln-Arg Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O DTRUBYPMMVPQPD-YUMQZZPRSA-N 0.000 description 5
- SWQALSGKVLYKDT-ZKWXMUAHSA-N Gly-Ile-Ala Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O SWQALSGKVLYKDT-ZKWXMUAHSA-N 0.000 description 5
- HJARVELKOSZUEW-YUMQZZPRSA-N Gly-Pro-Gln Chemical compound [H]NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O HJARVELKOSZUEW-YUMQZZPRSA-N 0.000 description 5
- KSOBNUBCYHGUKH-UWVGGRQHSA-N Gly-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN KSOBNUBCYHGUKH-UWVGGRQHSA-N 0.000 description 5
- AQCUAZTZSPQJFF-ZKWXMUAHSA-N Ile-Ala-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O AQCUAZTZSPQJFF-ZKWXMUAHSA-N 0.000 description 5
- YFBBUHJJUXXZOF-UWVGGRQHSA-N Leu-Gly-Pro Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O YFBBUHJJUXXZOF-UWVGGRQHSA-N 0.000 description 5
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 5
- 108010079364 N-glycylalanine Proteins 0.000 description 5
- ZPPVJIJMIKTERM-YUMQZZPRSA-N Pro-Gln-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]1CCCN1 ZPPVJIJMIKTERM-YUMQZZPRSA-N 0.000 description 5
- MIJWOJAXARLEHA-WDSKDSINSA-N Ser-Gly-Glu Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O MIJWOJAXARLEHA-WDSKDSINSA-N 0.000 description 5
- WFENBJPLZMPVAX-XVKPBYJWSA-N Val-Gly-Glu Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O WFENBJPLZMPVAX-XVKPBYJWSA-N 0.000 description 5
- AEFJNECXZCODJM-UWVGGRQHSA-N Val-Val-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C(=O)NCC([O-])=O AEFJNECXZCODJM-UWVGGRQHSA-N 0.000 description 5
- 108010047495 alanylglycine Proteins 0.000 description 5
- 108010078144 glutaminyl-glycine Proteins 0.000 description 5
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 5
- 108010050848 glycylleucine Proteins 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 230000007704 transition Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- RTZCUEHYUQZIDE-WHFBIAKZSA-N Ala-Ser-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RTZCUEHYUQZIDE-WHFBIAKZSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 206010053615 Thermal burn Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000001976 enzyme digestion Methods 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000004745 nonwoven fabric Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- AUFHLLPVPSMEOG-YUMQZZPRSA-N Arg-Gly-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O AUFHLLPVPSMEOG-YUMQZZPRSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- FUTAPPOITCCWTH-WHFBIAKZSA-N Gly-Asp-Asp Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O FUTAPPOITCCWTH-WHFBIAKZSA-N 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101150008132 NDE1 gene Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- IOVBCLGAJJXOHK-SRVKXCTJSA-N Ser-His-His Chemical compound C([C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 IOVBCLGAJJXOHK-SRVKXCTJSA-N 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- SGAOHNPSEPVAFP-ZDLURKLDSA-N Thr-Ser-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SGAOHNPSEPVAFP-ZDLURKLDSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 108010028295 histidylhistidine Proteins 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 108010060175 trypsinogen activation peptide Proteins 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Biophysics (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020114300308 | 2020-12-09 | ||
CN202011430030 | 2020-12-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112745394A true CN112745394A (zh) | 2021-05-04 |
CN112745394B CN112745394B (zh) | 2022-12-06 |
Family
ID=75653407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110128601.0A Active CN112745394B (zh) | 2020-12-09 | 2021-01-29 | 一种重组类人胶原蛋白及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112745394B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114853881A (zh) * | 2022-05-24 | 2022-08-05 | 华南理工大学 | 一种重组人源融合胶原蛋白及其高效羟基化方法与应用 |
CN116574172A (zh) * | 2023-06-07 | 2023-08-11 | 广州暨南大学医药生物技术研究开发中心有限公司 | 重组人源化i型胶原蛋白及其制备方法 |
CN116640231A (zh) * | 2023-06-09 | 2023-08-25 | 广州暨南大学医药生物技术研究开发中心有限公司 | 一种重组人源化17型胶原多肽及其制备方法 |
CN116970071A (zh) * | 2023-09-22 | 2023-10-31 | 英特菲尔(成都)生物制品有限责任公司 | 一种具有抗衰活性的重组弹性蛋白及其制备方法与应用 |
CN117327170A (zh) * | 2023-09-19 | 2024-01-02 | 广州高泰生物科技有限公司 | 一种类人胶原蛋白制备方法及其在化妆品中的应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5969106A (en) * | 1996-08-07 | 1999-10-19 | The Hospital For Sick Children | Self-aligning peptides modeled on human elastin and other fibrous proteins |
US20060248603A1 (en) * | 2002-12-27 | 2006-11-02 | Applied Research Systems Ars Holding N.V. | Novel fibrillin-like polypeptides |
CN104098701A (zh) * | 2014-07-23 | 2014-10-15 | 广州市暨鹏生物科技有限公司 | 重组类人胶原蛋白-人细胞生长因子融合蛋白及其制备方法与应用 |
CN109431856A (zh) * | 2018-12-17 | 2019-03-08 | 广州暨南大学医药生物技术研究开发中心 | 一种模拟细胞外基质的冻干产品 |
CN110343183A (zh) * | 2018-04-03 | 2019-10-18 | 点斗基因科技(南京)有限公司 | 一种重组表达载体及其构建方法和应用 |
CN111944057A (zh) * | 2020-07-23 | 2020-11-17 | 广州启妆生物科技有限公司 | 一种重组人胶原蛋白肽及其应用 |
-
2021
- 2021-01-29 CN CN202110128601.0A patent/CN112745394B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5969106A (en) * | 1996-08-07 | 1999-10-19 | The Hospital For Sick Children | Self-aligning peptides modeled on human elastin and other fibrous proteins |
US20060248603A1 (en) * | 2002-12-27 | 2006-11-02 | Applied Research Systems Ars Holding N.V. | Novel fibrillin-like polypeptides |
CN104098701A (zh) * | 2014-07-23 | 2014-10-15 | 广州市暨鹏生物科技有限公司 | 重组类人胶原蛋白-人细胞生长因子融合蛋白及其制备方法与应用 |
CN110343183A (zh) * | 2018-04-03 | 2019-10-18 | 点斗基因科技(南京)有限公司 | 一种重组表达载体及其构建方法和应用 |
CN109431856A (zh) * | 2018-12-17 | 2019-03-08 | 广州暨南大学医药生物技术研究开发中心 | 一种模拟细胞外基质的冻干产品 |
CN111944057A (zh) * | 2020-07-23 | 2020-11-17 | 广州启妆生物科技有限公司 | 一种重组人胶原蛋白肽及其应用 |
Non-Patent Citations (2)
Title |
---|
TIANZHI LUO ET AL: "Thermoresponsive elastin-b-collagen-like peptide bioconjugate nanovesicles for targeted drug delivery to collagen-containing matrices", 《BIOMACROMOLECULES》 * |
顾其胜 等: "《实用生物医学材料学》", 30 September 2005, 上海科学技术出版社 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114853881A (zh) * | 2022-05-24 | 2022-08-05 | 华南理工大学 | 一种重组人源融合胶原蛋白及其高效羟基化方法与应用 |
CN114853881B (zh) * | 2022-05-24 | 2023-06-16 | 华南理工大学 | 一种重组人源融合胶原蛋白及其高效羟基化方法与应用 |
CN116574172A (zh) * | 2023-06-07 | 2023-08-11 | 广州暨南大学医药生物技术研究开发中心有限公司 | 重组人源化i型胶原蛋白及其制备方法 |
CN116574172B (zh) * | 2023-06-07 | 2024-03-26 | 广州暨南大学医药生物技术研究开发中心有限公司 | 重组人源化i型胶原蛋白及其制备方法 |
CN116640231A (zh) * | 2023-06-09 | 2023-08-25 | 广州暨南大学医药生物技术研究开发中心有限公司 | 一种重组人源化17型胶原多肽及其制备方法 |
CN116640231B (zh) * | 2023-06-09 | 2024-03-26 | 广州暨南大学医药生物技术研究开发中心有限公司 | 一种重组人源化17型胶原多肽及其制备方法 |
CN117327170A (zh) * | 2023-09-19 | 2024-01-02 | 广州高泰生物科技有限公司 | 一种类人胶原蛋白制备方法及其在化妆品中的应用 |
CN117327170B (zh) * | 2023-09-19 | 2024-03-19 | 广州高泰生物科技有限公司 | 一种类人胶原蛋白制备方法及其在化妆品中的应用 |
CN116970071A (zh) * | 2023-09-22 | 2023-10-31 | 英特菲尔(成都)生物制品有限责任公司 | 一种具有抗衰活性的重组弹性蛋白及其制备方法与应用 |
CN116970071B (zh) * | 2023-09-22 | 2023-12-01 | 英特菲尔(成都)生物制品有限责任公司 | 一种具有抗衰活性的重组弹性蛋白及其制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
CN112745394B (zh) | 2022-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112745394B (zh) | 一种重组类人胶原蛋白及其制备方法和应用 | |
AU2016101562A4 (en) | Genetic recombinant human collagen, gene encoding the same, and preparation method thereof | |
CN110606896B (zh) | 重组人源III型胶原蛋白α1链及其应用 | |
CN113717290B (zh) | 一种复合透皮重组纤连蛋白及其应用 | |
CN108794639B (zh) | 一种重组纤连蛋白及其应用 | |
CN110845603B (zh) | 人胶原蛋白17型多肽、其生产方法和用途 | |
CN110204608A (zh) | 一种酵母发酵小分子重组纤连蛋白肽及其制备方法和应用 | |
WO2024002149A1 (zh) | 一种重组iii型胶原蛋白及其制备方法 | |
CN106519042A (zh) | 人源胶原蛋白与抗菌肽的融合蛋白及其制备方法与编码基因 | |
CN103468771B (zh) | 一种从牛跟腱中提取胶原的方法 | |
BR0211435B1 (pt) | Método de produção de polipeptídeo glp-1 insulinotrópico (7-36) e/ou análogos de glp | |
CN112661856A (zh) | 一种elp类胶原蛋白的纯化方法及应用 | |
CN116535520A (zh) | 一种细胞外基质蛋白融合蛋白及其制备方法和应用 | |
CN114316030B (zh) | 一种透皮吸收性的i型重组胶原蛋白及其用途 | |
CN103834664B (zh) | 重组表皮生长因子egf及其制备方法 | |
CN112851791B (zh) | 一种新型抗代谢紊乱的fgf类似物及其应用 | |
WO2023143396A1 (zh) | 高透皮吸收性肽及通过该肽的重复构建的重组胶原蛋白 | |
CN107308441A (zh) | 干细胞培养上清凝胶组合物及其制备方法和应用 | |
CN113880941B (zh) | 重组人源IxIII胶原蛋白、表达菌株及其应用 | |
CN110627889B (zh) | 重组蜘蛛丝蛋白及其制备方法和产业化应用 | |
CN111424035A (zh) | 基于家蚕丝腺表达具有生物学活性的人结缔组织生长因子的方法及其产品和应用 | |
CN110256572A (zh) | 一种rhc-(rada)4融合蛋白 | |
CN116640231B (zh) | 一种重组人源化17型胶原多肽及其制备方法 | |
CN117466992B (zh) | 一种纤连蛋白突变体及其制备和应用 | |
CN110498859B (zh) | 重组PLB-hbFGF融合蛋白及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240522 Address after: No. 201, 2nd Floor, Building E, No. 64 Songshan Road, Shilou Town, Panyu District, Guangzhou City, Guangdong Province, 510000 Patentee after: TAIYUAN (GUANGZHOU) BIOTECHNOLOGY CO.,LTD. Country or region after: China Address before: 511440 No. 201, Floor 2, No. 64 Songshan Road, Shilou Town, Panyu District, Guangzhou, Guangdong Patentee before: TAIYUAN (GUANGZHOU) BIOTECHNOLOGY CO.,LTD. Country or region before: China Patentee before: Guangzhou Jinan University Medical Biotechnology Research and Development Center Co.,Ltd. |